Functional testing methods for the antiplatelet effects of aspirin

Biomarkers in Medicine

Volumn 5, Issue 1, 2011, Pages 31-42

  Schrör, Karsten ^a   Huber, Kurt ^b   Hohlfeld, Thomas ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

aspirin; biomarker; flow cytometry; platelet function tests; thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BETA THROMBOGLOBULIN; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; INTERLEUKIN 6; PADGEM PROTEIN; THROMBOXANE A2; THROMBOXANE B2;

ACUTE HEART INFARCTION; ARACHIDONIC ACID METABOLISM; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING TIME; BLOOD EXAMINATION; FLOW CYTOMETRY; HUMAN; IMPEDANCE AGGREGATION; LIGHT TRANSMISSION AGGREGATION; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PLATELET AGGREGOMETRY; PREDICTIVE VALUE; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SHEAR INDUCED AGGREGATION; SHEAR STRESS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; SURFACE ADHESION AGGREGATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; UNSTABLE ANGINA PECTORIS; URINARY EXCRETION;

ANIMALS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 79951782413     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.122     Document Type: Review

References (74)

1. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
2. Baigent C, Blackwell L, Collins R et al.: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678), 1849-1860 (2009).
3. Mukherjee D, Topol EJ: Pharmacogenomics in cardiovascular diseases. Prog. Cardiovasc. Dis. 44(6), 479-498 (2002). (Pubitemid 34680195)
4. Gawaz M: Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc. Res. 61(3), 498-511 (2004). (Pubitemid 38210155)
5. Cattaneo M: Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J. Thromb. Haemost. 5(Suppl. 1), 230-237 (2007). (Pubitemid 46958838)
6. Davi G, Patrono C: Platelet activation and atherothrombosis. N. Engl. J. Med. 357(24), 2482-2494 (2007).
7. Bhatt DL, Topol EJ: Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discov. 2(1), 15-28 (2003). (Pubitemid 37361621)
8. Bretschneider E, Glusa E, Schror K: ADP-, PAF-and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological external Ca++ concentrations. Thromb. Res. 75(3), 233-242 (1994).
9. Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA: The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 20(1), 7-11 (2009).
10. Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF: Effect of the concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb. Haemost. 62(3), 968-976 (1989). (Pubitemid 20005012)
11. Undas A, Brummel-Ziedins KE, Mann KG: Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 109(6), 2285-2292 (2007). (Pubitemid 46425865)
12. De Gaetano G, Cerletti C: Aspirin resistance: a revival of platelet aggregation tests? J. Thromb. Haemost. 1(9), 2048-2050 (2003).
13. Wu KK, Hoak JC: Increased platelet aggregates in patients with transient ischemic attacks. Stroke 6(5), 521-524 (1975).
14. Santilli F, Rocca B, De Cristofaro R et al.: Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin resistance. J. Am. Coll. Cardiol. 53(8), 667-677 (2009).
15. Williams CD, Cherala G, Serebruany V: Application of platelet function testing to the bedside. Thromb. Haemost. 103(1), 29-33 (2010).
16. Gachet C, Aleil B: Testing antiplalet therapy. Eur. Heart J. 10(Suppl . A), A28-A34 (2008).
17. Gurbel PA, Bliden KP, DiChiara J et al.: Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25), 3156-3164 (2007). nn (Pubitemid 47012230)
18. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 28(14), 1702-1708 (2007). (Pubitemid 47227104)
19. Fontana P, Nolli S, Reber G, de Moerloose P: Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J. Thromb. Haemost. 4(4), 813-819 (2006).
20. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V: Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 36(2), 276-280 (2005). (Pubitemid 40170808)
21. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H: Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J. Neurol. 250(1), 63-66 (2003). (Pubitemid 36206686)
22. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM: Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36(5), 1001-1005 (2005). (Pubitemid 40629292)
23. Gum PA, Kottke-Marchant K, Poggio ED et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88(3), 230-235 (2001). (Pubitemid 32721947)
24. Frelinger AL 3rd, Furman MI, Linden MD et al.: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113(25), 2888-2896 (2006). (Pubitemid 44297229)
25. Grosser T, Fries S, Lawson J, FitzGerald GA: Variability in the response to aspirin. Circulation 120, S1032 (2009) (Abstract 5007).
26. Meen O, Brosstad F, Khiabani H et al.: No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand. J. Clin. Lab. Invest. 68(3), 185-191 (2008). (Pubitemid 351630829)
27. van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM: The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 19(7), 479-488 (2008).
28. Michelson AD: Flow cytometry: a clinical test of platelet function. Blood 87(12), 4925-4936 (1996). (Pubitemid 26189833)
29. Fox SC, May JA, Shah A, Neubert U, Heptinstall S: Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 20(4), 250-259 (2009).
30. Vandendries ER, Furie BC, Furie B: Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb. Haemost. 92(3), 459-466 (2004). (Pubitemid 39248002)
31. Gurbel PA, Bliden KP: The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy. Thromb. Res. 112(1-2), 9-12 (2003).
32. Henn V, Slupsky JR, Grafe M et al.: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391(6667), 591-594 (1998). (Pubitemid 28157601)
33. Michelson AD: Methods for the measurement of platelet function. Am. J. Cardiol. 103(Suppl. 3), 20A-26A (2009).
34. Weber AA, Przytulski B, Schumacher M et al.: Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting. Br. J. Haematol. 117(2), 424-426 (2002). (Pubitemid 34451160)
35. Enomoto Y, Adachi S, Matsushima-Nishiwaki R et al.: Thromboxane A2 promotes soluble CD40 ligand release from human platelets. Atherosclerosis 209(2), 415-421 (2010).
36. Weber AA, Hermann A, Rauch BH, Schrör K: Molecular identity of platelet CD40 ligand (CD40L). Thromb. Haemost. 86(2), 718 (2001). (Pubitemid 32743295)
37. Hermann A, Rauch BH, Braun M, Schror K, Weber AA: Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12(2), 74-82 (2001) (Pubitemid 32281113)
38. Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P: Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin. Biochem. 43(7-8), 666-670 (2010).
39. Ulrych T, Böhm A, Polzin A et al.: Release of sphingosine-1- phosphate from human platelets is dependent on thromboxane formation. J. Thromb. Haemost. DOI: 10.1111/j.1538-7836.2011.04194.x (2010) (Epub ahead of print). nn
40. Hohlfeld T, Weber AA, Junghans U et al.: Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc. Dis. 24(1), 43-50 (2007). (Pubitemid 47026140)
41. Pulcinelli FM, Riondino S, Celestini A et al.: Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. J. Thromb. Haemost. 3(12), 2784-2789 (2005). (Pubitemid 41819808)
42. Zimmermann N, Wenk A, Kim U et al.: Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108(5), 542-547 (2003). (Pubitemid 36961167)
43. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K: Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 353(9156), 900 (1999). (Pubitemid 29126885)
44. Szczeklik A, Musial J, Undas A, Sanak M: Aspirin resistance. J. Thromb. Haemost. 3(8), 1655-1662 (2005). (Pubitemid 41716551)
45. Rocca B, Secchiero P, Ciabattoni G et al.: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc. Natl Acad. Sci. USA 99(11), 7634-7639 (2002). (Pubitemid 34568743)
46. Matijevic-Aleksic N, Sanduja SK, Wang LH, Wu KK: Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Biochim. Biophys. Acta 1269(2), 167-175 (1995).
47. Catella F, Healy D, Lawson JA, FitzGerald GA: 11-dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc. Natl Acad. Sci. USA 83(16), 5861-5865 (1986). (Pubitemid 16000613)
48. Roberts LJ 2nd, Sweetman BJ, Oates JA: Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J. Biol. Chem. 256(16), 8384-8393 (1981). (Pubitemid 12254787)
49. Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C: Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim. Biophys. Acta 992(1), 66-70 (1989). (Pubitemid 19179025)
50. Uedelhoven WM, Rutzel A, Meese CO, Weber PC: Smoking alters thromboxane metabolism in man. Biochim. Biophys. Acta 1081(2), 197-201 (1991).
51. Nüsing R, Ullrich V: Immunoquantitation of thromboxane synthase in human tissues. Adv. Prostaglandin Thromboxane Leukot. Res. 21A, 307-310 (1991).
52. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100(8), 793-798 (1999). (Pubitemid 29398875)
53. Trip MD, Cats VM, van Capelle FJ, Vreeken J: Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N. Engl. J. Med. 322(22), 1549-1554 (1990). (Pubitemid 20176694)
54. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43(6), 1122-1126 (2004). (Pubitemid 38353000)
55. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. 41(6), 961-965 (2003). (Pubitemid 36315537)
56. Valles J, Santos MT, Fuset MP et al.: Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. 99(1), 19-25 (2007). (Pubitemid 44969337)
57. Ashley KE, Lincoff AM: Pharmacologic inhibition of platelet function: correlation between in vitro tests of platelet function and clinical outcomes. Am. J. Cardiovasc. Drugs 8(5), 283-295 (2008).
58. Chen WH, Cheng X, Lee PY et al.: Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am. J. Med. 120(7), 631-635 (2007). (Pubitemid 46977320)
59. Buch AN, Singh S, Roy P et al.: Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 99(11), 1518-1522 (2007). (Pubitemid 46770633)
60. Dorsch MP, Lee JS, Lynch DR et al.: Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann. Pharmacother. 41(5), 737-741 (2007). (Pubitemid 46752652)
61. Frelinger AL 3rd, Li Y, Linden MD et al.: Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120(25), 2586-2596 (2009).
62. Catella F, Lawson JA, Fitzgerald DJ, FitzGerald GA: Analysis of multiple thromboxane metabolites in plasma and urine. Adv. Prostaglandin Thromboxane Leukot. Res. 17B, 611-614 (1987).
63. Cipollone F, Ciabattoni G, Patrignani P et al.: Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102(9), 1007-1013 (2000). (Pubitemid 30657517)
64. Frelinger AL, Li Y, Linden MD et al.: Aspirin resistance: role of pre-existent platelet reactivity and correlation between tests. J. Thromb. Haemost. 6(12), 2035-2044 (2008).
65. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105(14), 1650-1655 (2002). (Pubitemid 34298607)
66. Eikelboom JW, Hankey GJ, Thom J et al.: Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118(17), 1705-1712 (2008).
67. Ohmori T, Yatomi Y, Nonaka T et al.: Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 4(6), 1271-1278 (2006).
68. Bahr RD, Gurbel PA, Malinin AI et al.: Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. Am. J. Cardiol. 90(3), 310-312 (2002). (Pubitemid 34804567)
69. Schrör K, Hohlfeld T, Weber AA: Aspirin resistance - does it clinically matter? Clin. Res. Cardiol. 95(10), 505-510 (2006). (Pubitemid 44496713)
70. Tran HA, Anand SS, Hankey GJ, Eikelboom JW: Aspirin resistance. Thromb. Res. 120(3), 337-346 (2007). (Pubitemid 46879910)
71. Montalescot G, Maclouf J, Drobinski G, Salloum J, Grosgogeat Y, Thomas D: Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J. Am. Coll. Cardiol. 24(1), 33-38 (1994). (Pubitemid 24202773)
72. Uyama O, Matsui Y, Shimizu S, Michishita H, Sugita M: Risk factors for carotid atherosclerosis and platelet activation. Jpn Circ. J. 58(6), 409-415 (1994). (Pubitemid 24236596)
73. Bruno A, McConnell JP, Mansbach HH 3rd, Cohen SN, Tietjen GE, Bang NU: Aspirin and urinary 11-dehydrothromboxane B2 in African American stroke patients. Stroke 33(1), 57-60 (2002). (Pubitemid 34052185)
74. Ikonomidis I, Andreotti F, Nihoyannopoulos P: Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. Heart 90(4), 389-393 (2004). (Pubitemid 38406911)